Document is current
Any future updates will be listed below
-
Authors
Corria-Osorio, Jesus https://orcid.org/0000-0001-6844-6170
Carmona, Santiago J. https://orcid.org/0000-0002-2495-0671
Stefanidis, Evangelos
Andreatta, Massimo https://orcid.org/0000-0002-8036-2647
Ortiz-Miranda, Yaquelin https://orcid.org/0000-0002-9136-6205
Muller, Tania
Rota, Ioanna A.
Crespo, Isaac
Seijo, Bili
Castro, Wilson https://orcid.org/0000-0002-9649-9883
Jimenez-Luna, Cristina https://orcid.org/0000-0002-2395-1728
Scarpellino, Leonardo
Ronet, Catherine
Spill, Aodrenn
Lanitis, Evripidis
Romero, Pedro https://orcid.org/0000-0002-9688-2882
Luther, Sanjiv A. https://orcid.org/0000-0002-8758-957X
Irving, Melita https://orcid.org/0000-0002-6849-7194
Coukos, George https://orcid.org/0000-0001-8813-7367
- License Information
-
More Information
Article History
Received: 28 March 2022
Accepted: 1 March 2023
First Online: 20 April 2023
Competing interests
: G.C. has received grants and research support or is co-investigator in clinical trials by Bristol Myers Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance Biotherapeutics and Kite. Lausanne University Hospital (CHUV) has received honoraria for advisory services. G.C. has also received honoraria for advisory services provided to AstraZeneca, Bristol Myers Squibb, F. Hoffmann-La Roche, MSD Merck and Geneos Therapeutics. G.C. has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T-cell expansion and engineering for T-cell therapy. G.C. receives royalties from the University of Pennsylvania. J.C.-O. has patents in the domain of immune cytokines (TGF-β mutants) as well as in technologies related to T-cell expansion and engineering for T-cell therapy. The other authors declare no competing interests.
